GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sucampo Pharmaceuticals Inc (NAS:SCMP) » Definitions » Book Value per Share

Sucampo Pharmaceuticals (Sucampo Pharmaceuticals) Book Value per Share : $0.85 (As of Sep. 2017)


View and export this data going back to 2007. Start your Free Trial

What is Sucampo Pharmaceuticals Book Value per Share?

Sucampo Pharmaceuticals's book value per share for the quarter that ended in Sep. 2017 was $0.85.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

Sucampo Pharmaceuticals's current price is $18.00. Its book value per share for the quarter that ended in Sep. 2017 was $0.85. Hence, today's PB Ratio of Sucampo Pharmaceuticals is 21.18.


Sucampo Pharmaceuticals Book Value per Share Historical Data

The historical data trend for Sucampo Pharmaceuticals's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sucampo Pharmaceuticals Book Value per Share Chart

Sucampo Pharmaceuticals Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.03 1.36 1.85 1.90 3.60

Sucampo Pharmaceuticals Quarterly Data
Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.16 3.60 3.75 0.57 0.85

Competitive Comparison of Sucampo Pharmaceuticals's Book Value per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Sucampo Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sucampo Pharmaceuticals's PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sucampo Pharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where Sucampo Pharmaceuticals's PB Ratio falls into.



Sucampo Pharmaceuticals Book Value per Share Calculation

Sucampo Pharmaceuticals's Book Value Per Share for the fiscal year that ended in Dec. 2016 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(167.1-0.0)/46.4
=3.60

Sucampo Pharmaceuticals's Book Value Per Share for the quarter that ended in Sep. 2017 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(39.6-0.0)/46.6
=0.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Sucampo Pharmaceuticals  (NAS:SCMP) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Sucampo Pharmaceuticals Book Value per Share Related Terms

Thank you for viewing the detailed overview of Sucampo Pharmaceuticals's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Sucampo Pharmaceuticals (Sucampo Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
Sucampo Pharmaceuticals Inc is a part of the healthcare sector in the United States. As a global pharmaceutical company, it commercializes drugs for the treatment of various gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It currently generates revenue mainly from product royalties, product sales, upfront and milestone payments, and reimbursements for development activities.
Executives
Peter Greenleaf officer: Chief Executive Officer ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Maureen Oconnell director
Karen L. Smith director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Jones W. Bryan officer: Sr. Vice Pres., BD & Licensing C/O SUPERNUS PHARMACEUTICALS, INC., 1550 EAST GUDE DRIVE, ROCKVILLE MD 20850
Robert J. Spiegel director C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Timothy P Walbert director 1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062
Peter A Kiener officer: Chief Science Officer 40 GUEST STREET, BOSTON MA 02135
John Johnson director DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Peter P. Pfreundschuh officer: CFO C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Paul R Edick director C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010
Thomas J Knapp other: Former Officer 4640 SW MACADAM AVE., SUITE 270, PORTLAND OR 97239
William Ashton director C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Timothy I Maudlin director 18739 VOGEL FARM TRAIL, EDEN PRAIRIE MN 55347
Nantahala Capital Management, Llc 10 percent owner 130 MAIN ST., 2ND FLOOR, NEW CANAAN CT 06840
Mariam E Morris officer: Chief Acctg. Officer, Treas. C/O SUCAMPO PHARMACEUTICALS, 4520 EAST-WEST HIGHWAY, SUITE 300, BETHESDA MD 20814

Sucampo Pharmaceuticals (Sucampo Pharmaceuticals) Headlines